← FDA DRUG APPROVALS

FDA ANDA · ANDA207066

NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

norethindrone and ethinyl estradiol and ferrous fumarate tablet

Sponsor: NAARI PTE

APPLICATION
ANDA207066
TYPE
ANDA
ORIGINAL APPROVAL
2017-03-29
LATEST ACTION
2022-04-29
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATEPrescription
ETHINYL ESTRADIOL 0.035MG, NORETHINDRONE 0.4MG · TABLET · ORAL

Approval history

2022-04-29Labeling · Supplement 2 · standardAP
2017-03-29UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →